Target intelligence / Profile preview

Tight junction protein ZO-1 and Occludin (ZO-1 and Occludin)

Target
ZO-1 and Occludin
Molecular classification
Scaffold protein (ZO-1), Peripheral membrane protein (ZO-1), Tight junction-associated protein (both), Transmembrane protein (Occludin), Other
01

Overview

Tight junction protein ZO-1 and Occludin are key structural and regulatory components of tight junctions, which form selective barriers between adjacent epithelial or endothelial cells[1][2][5][6]. **ZO-1** is a scaffold protein encoded by the TJP1 gene; it is located on the cytoplasmic side of the cell membrane and organizes tight junctions by connecting transmembrane proteins (like occludin and claudins) to the actin cytoskeleton, thereby maintaining barrier selectivity and epithelial polarity[1][5][6][7]. Its multi-domain structure enables binding to numerous junctional proteins and cytoskeletal elements, playing roles in cytoskeletal organization, signal transduction, and mechanotransduction[2][5]. **Occludin** is a transmembrane protein spanning the membrane four times, with extracellular loops mediating intercellular adhesion and a C-terminal domain that interacts with ZO-1, essential for its trafficking and function at tight junctions[2][6]. Both proteins regulate the permeability of the paracellular pathway and participate in non-canonical functions such as apoptosis regulation, mechanosensing, and gene expression changes. Dysfunction or altered expression of ZO-1 and Occludin is implicated in a variety of diseases involving barrier breakdown, making them informative biomarkers and potential—but challenging—therapeutic targets[2][6][7].

Other names
Zonula occludens-1Tight junction protein 1TJP1OCLN
02

Mechanism of action

Enhancement or restoration of tight junction integrity (indirect, via pathway modulation). Reduction of paracellular leak by stabilizing protein-protein or protein-cytoskeleton interactions. Inhibition of protein phosphorylation or disruption of scaffolding complex[4][7].

03

Biological functions

Maintenance of tight junction barrier functionRegulation of paracellular permeabilityScaffolding and organization of tight/adherens junctionsSignal transduction at cell-cell contactsRegulation of cytoskeleton organizationCell polarity maintenanceEpithelial and endothelial barrier functionRegulation of epithelial apoptosis (non-canonical function)[2][5][6]
04

Disease associations

Cancer (altered expression or localization in several cancers)Inflammation (disruption contributes to inflammatory diseases)Infection (targeted by bacterial/viral toxins leading to barrier dysfunction)Neurodegenerative disease (blood-brain barrier integrity)Cardiovascular disease (vascular permeability)Other (observed in various tissue injuries and autoimmune disorders)[2][6]
05

Safety considerations

Modulation may cause excessive tightening or loosening of barriers, risking tissue edema or impaired nutrient/drug deliveryDisruption can contribute to leaky barrier syndromes or increased susceptibility to pathogensTargeting may have off-target or systemic effects due to broad tissue distribution
06

Interacting drugs

No current FDA-approved direct drugs, but modulators include: Myosin light chain kinase inhibitors (indirect barrier modulation)

3 more in the full profile.

07

Biomarkers

ZO-1 and Occludin immunohistochemical staining for barrier integrity in tissuesBiomarker of epithelial/endothelial barrier status (e.g., in colon, lung, brain)Used to monitor drug-induced or disease-induced barrier disruption in research and clinical pathology[6]

Beyond the preview

Go deeper on Tight junction protein ZO-1 and Occludin (ZO-1 and Occludin).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tight junction protein ZO-1 and Occludin (ZO-1 and Occludin).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call